These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2517439)

  • 1. Weakening of antigen D and development of anti-D in a patient with acute myeloid leukaemia.
    Mujeeb SA; Siddiqui S; Khursheed T; Hashmi MR
    J Pak Med Assoc; 1989 Dec; 39(12):324-5. PubMed ID: 2517439
    [No Abstract]   [Full Text] [Related]  

  • 2. [Qualitative and quantitative study of a DVI variant with anti-D in the serum].
    Puig N; Carbonell F; Arriaga F; Lorenzo I; Montoro JA; Soler A; Pérez-Castellanos T; Miravalls C; Marty ML
    Sangre (Barc); 1986; 31(3):335-9. PubMed ID: 3092375
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-transplant induction of donor-type anti-RhD antibodies production shortly followed by complete hemolysis of recipient-type erythrocytes in RhD-mismatched allogeneic bone marrow recipient.
    Markiewicz M; Wojnar J; Giebel S; Wieczorkiewicz A; Wylezoł I; Hołowiecki J
    Bone Marrow Transplant; 2006 Feb; 37(4):433-4. PubMed ID: 16400335
    [No Abstract]   [Full Text] [Related]  

  • 4. Complement dependent cytotoxic autoantibodies in patients with acute leukaemia following fibrinolytic therapy by protease 1 of aspergillus oryzae.
    Thornes RD; Kee JL; Devlin JG; MacDonell JD
    Ir J Med Sci; 1970 Mar; 3(3):107-14. PubMed ID: 5268985
    [No Abstract]   [Full Text] [Related]  

  • 5. Acquired auto-anti D in a patient with myelodysplastic syndrome.
    Yermiahu T; Dvilansky A; Avinoam I; Benharroch D
    Sangre (Barc); 1991 Feb; 36(1):47-9. PubMed ID: 1906640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hemolytic anemia with anti-N and anti-e autoantibodies].
    Kout M; Chrobák L; Podzimek K
    Vnitr Lek; 1981 Jun; 27(6):592-7. PubMed ID: 6791376
    [No Abstract]   [Full Text] [Related]  

  • 7. [Distribution of the ABO and Rh-D systems in leukemic patients].
    Gurda M; Turowska B
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 94(4):303-8. PubMed ID: 4101120
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of HLA, ABO, and Rh(D) on survival after remission in acute myelogenous leukaemia.
    Harris R; Zuhrie SR; Taylor GM; Freeman CB; Wentzel J; Geary C; MacIver JE
    Lancet; 1977 Sep; 2(8039):653. PubMed ID: 71463
    [No Abstract]   [Full Text] [Related]  

  • 9. [Erythrocyte detection with the immunoperoxidase method following 2 failed transfusions in ABO and Rhesus incompatibility--clinical course].
    Heim MU; Pachmann U; Böck M; Geschwändler E; Schleifer A; Eckstein R; Mempel W
    Beitr Infusionsther; 1988; 21():255-8. PubMed ID: 2462987
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of a full-term infant with hemolytic disease of the newborn due to an anti-Rh17 antibody in a mother with D-- phenotype.
    Shah SI; Caprio M; Strauss R; Moskowitz N
    Am J Hematol; 2005 Sep; 80(1):88-9. PubMed ID: 16138349
    [No Abstract]   [Full Text] [Related]  

  • 11. Frequency and specificity of red cell antibodies in thalassemia patients in Albania.
    Seferi I; Xhetani M; Face M; Burazeri G; Nastas E; Vyshka G
    Int J Lab Hematol; 2015 Aug; 37(4):569-74. PubMed ID: 25865362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red blood cell survival evaluated by RhD-negative cells transfused into RhD-positive patients.
    Onozaki F; Kishino K; Muroi K
    Transfus Apher Sci; 2015 Jun; 52(3):317-8. PubMed ID: 25634789
    [No Abstract]   [Full Text] [Related]  

  • 13. Rh-incompatible platelet transfusions--risks and consequences of sensitizing immunosuppressed patients.
    Goldfinger D; McGinniss MH
    N Engl J Med; 1971 Apr; 284(17):942-4. PubMed ID: 4994614
    [No Abstract]   [Full Text] [Related]  

  • 14. Transient presence of an anti-D alloantibody.
    Harrison CR; Evans C
    Arch Pathol Lab Med; 1985 Nov; 109(11):1042-3. PubMed ID: 3931606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supportive care in the management of acute myeloid leukaemia.
    Rajni A; Venugopal P; Saikia T; Gopal R; Kurkure PA; Pai SK; Pai VR; Nair CN; Nadkarni KS; Advani SH
    J Assoc Physicians India; 1987 Dec; 35(12):826-30. PubMed ID: 3482463
    [No Abstract]   [Full Text] [Related]  

  • 16. [Systematic study of autoantibodies and immune globulin anomalies in the course of several varieties of acute leukemias].
    Cannat A; Rain JD; Seligmann M; Thomas N
    Nouv Rev Fr Hematol; 1969; 9(2):290-4. PubMed ID: 4239789
    [No Abstract]   [Full Text] [Related]  

  • 17. [Controlled prophylaxis with immunoglobulin G anti-Rh (IgG anti-Rh) following mistaken Rh transfusion].
    Poschmann A; Fischer K; Hoppe HH; Welsch H
    Beitr Infusionther Klin Ernahr; 1979; (3):81-4. PubMed ID: 121699
    [No Abstract]   [Full Text] [Related]  

  • 18. Pregancy complicated by acute myeloid leukaemia.
    Hamer JW; Beard ME; Duff GB
    N Z Med J; 1979 Mar; 89(632):212-3. PubMed ID: 286907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved response of an Rh-positive patient with aplastic anemia to donor platelet transfusions with intravenous anti-D rhesus antibodies.
    Siemons L; Colpin G; Muylle L; De Bock R; Peetermans ME
    N Engl J Med; 1987 Dec; 317(26):1667-8. PubMed ID: 3120010
    [No Abstract]   [Full Text] [Related]  

  • 20. Blood group specificity of an autohemagglutinin induced by alpha-methyldopa therapy.
    Itoh Y; Yuasa S
    Nihon Hoigaku Zasshi; 1986 Feb; 40(1):30-4. PubMed ID: 3095573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.